Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein - Aix-Marseille Université Access content directly
Journal Articles Journal of Hepatocellular Carcinoma Year : 2018

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Jean-Luc Raoul

Abstract

Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.

Dates and versions

hal-02143684 , version 1 (29-05-2019)

Identifiers

Cite

Marine Gilabert, Jean-Luc Raoul. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. Journal of Hepatocellular Carcinoma, 2018, 5, pp.91-98. ⟨10.2147/JHC.S157413⟩. ⟨hal-02143684⟩

Collections

CNRS UNIV-AMU CRCM
11 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More